Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy

Tomoko Katsui Taniyama, Chigusa Morizane, Kohei Nakachi, Satoshi Nara, Hideki Ueno, Shunsuke Kondo, Tomoo Kosuge, Kazuaki Shimada, Minoru Esaki, Masafumi Ikeda, Shuichi Mitsunaga, Taira Kinoshita, Masaru Konishi, Shinichiro Takahashi, Takuji Okusaka

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Objectives: A global consensus on how to treat recurrent pancreatic cancer after adjuvant chemotherapy with gemcitabine (ADJ-GEM) does not exist. Methods: We retrospectively reviewed the clinical data of 41 patients with recurrences who were subsequently treated with chemotherapy. Results: The patients were divided into two groups according to the time until recurrence after the completion of ADJ-GEM (ADJ-Rec): patients with an ADJ-Rec < 6 months (n = 25) and those with an ADJ-Rec ≥ 6 months (n = 16). The disease control rate, the progression-free survival after treatment for recurrence and the overall survival after recurrence for these two groups were 68 and 94% (P = 0.066), 5.5 and 8.2 months (P = 0.186), and 13.7 and 19.8 months (P = 0.009), respectively. Furthermore, we divided the patients with an ADJ-Rec < 6 months into two groups: patients treated with gemcitabine (n = 6) and those treated with alternative regimens including fluoropyrimidine-containing regimens (n = 19) for recurrent disease. Patients treated with the alternative regimens had a better outcome than those treated with gemcitabine. Conclusions: Fluoropyrimidine- containing regimens may be a reasonable strategy for recurrent disease after ADJ-GEM and an ADJ-Rec < 6 months.

Original languageEnglish
Pages (from-to)428-433
Number of pages6
JournalPancreatology
Volume12
Issue number5
DOIs
StatePublished - 2012
Externally publishedYes

Keywords

  • Adjuvant chemotherapy
  • Chemotherapy
  • Gemcitabine
  • Recurrent pancreatic cancer
  • S-1

Fingerprint

Dive into the research topics of 'Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy'. Together they form a unique fingerprint.

Cite this